Tharimmune (NASDAQ: THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory and oncologic conditions, has announced the pricing of an underwritten public offering of 10,000,000 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock (or pre-funded warrant) is being sold at a public offering price of $1.00 per share (inclusive of the pre-funded warrant exercise price) for gross proceeds to Tharimmune of $10,000,000. All of the shares of common stock and pre-funded warrants are being offered by the company. In addition, Tharimmune granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock and/or pre-funded warrants to cover over-allotments at the public offering price, less the underwriting discount. The company intends to use the net proceeds for the advancement of TH104’s phase 2 trial expected in 2024, as well as for working capital and other general corporate purposes. Subject to the satisfaction of customary conditions, the offering is expected to close on Nov. 30, 2023. ThinkEquity is acting as sole book-running manager for the offering.
To view the full press release, visit https://ibn.fm/QVOjX
About Tharimmune Inc.
Tharimmune is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory and oncologic diseases. The company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan liver disease with no known cure. The company’s early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb Inc. to access the company’s antibody discovery technology platform against specified targets. For more information about the company, visit: www.Tharimmune.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
